DaVita (DVA) Stock Overview
Provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 1/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
DVA Community Fair Values
Create NarrativeSee what 43 others think this stock is worth. Follow their fair value or set your own to get alerts.
DaVita Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$134.73 |
| 52 Week High | US$178.47 |
| 52 Week Low | US$101.00 |
| Beta | 1.01 |
| 1 Month Change | 17.66% |
| 3 Month Change | 11.20% |
| 1 Year Change | -24.03% |
| 3 Year Change | 59.01% |
| 5 Year Change | 21.38% |
| Change since IPO | 3,206.25% |
Recent News & Updates
Recent updates
DaVita: Some Success Is Possible, But Volatility Is Still Heavy
Feb 03Investors Aren't Entirely Convinced By DaVita Inc.'s (NYSE:DVA) Earnings
Aug 05
Slowing Rates Of Return At DaVita (NYSE:DVA) Leave Little Room For Excitement
Jul 16We Ran A Stock Scan For Earnings Growth And DaVita (NYSE:DVA) Passed With Ease
Jun 28An Intrinsic Calculation For DaVita Inc. (NYSE:DVA) Suggests It's 49% Undervalued
May 27DaVita (NYSE:DVA) Has A Pretty Healthy Balance Sheet
May 12DaVita Inc.'s (NYSE:DVA) Prospects Need A Boost To Lift Shares
Apr 14Returns On Capital At DaVita (NYSE:DVA) Have Stalled
Apr 02We Ran A Stock Scan For Earnings Growth And DaVita (NYSE:DVA) Passed With Ease
Mar 20The DaVita Dilemma: Flat Patient Enrollment And Lawsuits, Yet An Improvement In Net Income Margin
Mar 17Is Now An Opportune Moment To Examine DaVita Inc. (NYSE:DVA)?
Mar 07DaVita: Momentum Could Fade Given High Valuation
Feb 05DaVita: Better Results Than Fresenius, But A 'Hold' Due To Valuation
Nov 14
Critical Investments And Policy Changes Propel Healthcare Innovator Towards Brighter Financial Horizons
DaVita's investments in technology and workforce initiatives aim to enhance revenue operations and patient care, contributing to future growth and profitability.DaVita Stock Is A Hold As It Expands In Latin America
Mar 18DaVita: Assessing After The Rally
Dec 29DaVita: Simple And Compelling After Sell-Off
Oct 26Shareholder Returns
| DVA | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 27.6% | -10.2% | -0.3% |
| 1Y | -24.0% | -22.8% | 14.5% |
Return vs Industry: DVA underperformed the US Healthcare industry which returned -22.8% over the past year.
Return vs Market: DVA underperformed the US Market which returned 14.5% over the past year.
Price Volatility
| DVA volatility | |
|---|---|
| DVA Average Weekly Movement | 3.5% |
| Healthcare Industry Average Movement | 7.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: DVA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: DVA's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 76,000 | Javier Rodriguez | www.davita.com |
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
DaVita Inc. Fundamentals Summary
| DVA fundamental statistics | |
|---|---|
| Market cap | US$7.62b |
| Earnings (TTM) | US$721.80m |
| Revenue (TTM) | US$13.64b |
Is DVA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DVA income statement (TTM) | |
|---|---|
| Revenue | US$13.64b |
| Cost of Revenue | US$9.24b |
| Gross Profit | US$4.40b |
| Other Expenses | US$3.68b |
| Earnings | US$721.80m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 10.53 |
| Gross Margin | 32.25% |
| Net Profit Margin | 5.29% |
| Debt/Equity Ratio | 886.8% |
How did DVA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/03 22:23 |
| End of Day Share Price | 2026/02/03 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
DaVita Inc. is covered by 30 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Gillmor | Baird |
| Steven Valiquette | Barclays |
| Andrew Mok | Barclays |